Pharma and vaccines · Switzerland and Germany

Your affiliate for Switzerland and Germany, on demand.

Two senior partners with more than 50 years of combined pharma leadership, most of it in vaccines, run your commercial and medical presence in both markets, without the cost and lead time of building a local organisation.

Track record

Vaccines are not one of our sectors. They are our careers.

Experience
50+

years of combined leadership, most of it in vaccines

Speed
2-4

weeks from agreement to an active mandate

Home markets
CHcovered by a Swiss national
DEcovered by a German national

No junior layer.

Every mandate is delivered by the two partners personally.

From Bern to Berlin, we know both markets from the inside.

Services

What a local affiliate does, without you building one.

Booked as an ongoing mandate or as a clearly defined project.

Market access and pricing

Market and competitive analysis, pricing and reimbursement strategy, business cases and forecasts that are ready for a decision.

Medical affairs and education

Medical education, expert and advisory programmes, stakeholder management and congress work, promotional or non-promotional.

Vaccine recommendations

Evidence and dialogue for recommendation bodies such as STIKO, from the first dossier to an expanded recommendation.

Launch and supply route

Wholesale and pharmacy channel, ordering and returns agreements, so that a product can actually be ordered.

Virtual pharma

We run the market for you. imunaris covers sales, medical affairs and marketing, our partner network covers marketing authorisation, quality assurance, logistics and order processing.

In-licensing and distribution

Product selection, licence negotiation, regulatory dossier and exclusive distribution for Switzerland.

Track record

What we have already achieved.

Selected results from our careers in the vaccine industry.

Travel medicine

Global launch of a Japanese encephalitis vaccine through the travel clinic channel, and global marketing lead for a travel vaccine portfolio worth USD 200 m.

Influenza and adjuvants

Swiss launch of the adjuvanted influenza vaccine Fluad, and years of medical affairs and market access work on seasonal and pandemic influenza.

Pandemic supply

H1N1 pandemic vaccine supply agreement with the Swiss federal health authority, and negotiations in European pandemic tenders that closed contracts in several countries.

Recommendation bodies

Medical and market access work with STIKO, ECDC, JCVI, ACIP and WHO that contributed to an expanded paediatric vaccine recommendation.

Global pricing and access

Global pricing strategy for a dengue vaccine across more than 20 launch countries, and a long-term PAHO supply agreement.

National launches

Rotavirus, MMRV and TBE vaccine launches in Switzerland, with the TBE market share raised from 20% to over 50%.

Current work

Running right now.

Client names stay with us. Status autumn 2026.

Global vaccine manufacturer

Active

Non-promotional reference materials and education for the Swiss pharmacy channel on RSV, shingles, influenza and further vaccines.

Vaccines · Switzerland

European vaccine manufacturer

Active

Market entry in Germany for an EU-approved vaccine, from pricing and ordering route to market launch.

Vaccines · Germany
AI in regulated pharma

AI that holds up in pharma.

We use AI where it makes processes leaner and teams more effective, and we help pharma companies do the same: from the first assessment to a validated solution in daily use.

Generated on our own hardware.
How we help you

AI readiness

Where does AI pay off in your company, and what has to be in place first? We assess processes, data and systems and show the quickest path to real value.

Implementation

From use case to daily operation: selection, set-up, validation and training of your teams, compliant with GxP and data protection, with local models on your own hardware where needed.

Digital processes

Manual and paper-based routines become lean digital workflows, so your experts spend their time where expertise counts.

Why we can

We use it ourselves

AI makes our own processes faster and leaner every day. We recommend what we run ourselves.

Pharma regulation from practice

More than 50 years of combined experience with Swiss and German pharma rules. We know where AI helps and where the rules draw the line.

Built to be validated

Our own AI-supported quality management system follows the GAMP 5 approach, with change control and documented model changes, and keeps the coming EU GMP Annex 22 on AI in view. In pilot with a Swiss wholesaler.

eQMS for wholesalers

Quality management for pharmaceutical wholesale.

The Responsible Person (FvP) is personally accountable for every supplier, every release and every regulatory change under Swiss law. Yet much of this work still runs on spreadsheets, paper checklists and e-mail. We are building an electronic quality management system for Swiss pharmaceutical wholesale that brings supplier qualification, goods receipt, document control and regulatory monitoring together, built on GDP and GAMP 5 principles, with a local AI model so sensitive data stays in-house. The FvP still decides every step.

In pilot with a Swiss wholesalerRequest early access
What it covers

Supplier and customer checks

Licences in the official registers are checked routinely instead of by hand, partner by partner.

Goods receipt without paper

Checks, deviations and releases in one place, traceable at any time.

Regulatory changes in view

New rules surface automatically, already mapped to the SOPs they affect.

Ready for inspection

Versioned, signed documents and a complete chain of evidence, without a last-minute search.

The partners

Two people, one table.

Founded in September 2025, when a vaccine close to our hearts lost its Swiss distributor and the manufacturer found no replacement because the market seemed too small. imunaris exists for exactly these products.

Daniel Fässler

Daniel Fässler, MBA

CEO, Commercial and Market Access

More than 20 years of commercial leadership in vaccines at GSK, Novartis and Takeda. Country Head Vaccines and Diagnostics Switzerland at Novartis, global marketing lead for a travel vaccine portfolio, and global pricing and market access for a dengue vaccine.

MBA, University of Rochester (Simon Business School). Background in chemistry and computer science.

LinkedIn
Dr. Eckhardt Petri

Dr. Eckhardt Petri, MHBA

CMO, Medical Affairs and Market Access

About 30 years in pharma, about 20 of them in medical affairs for vaccines and infectious disease. 8 years at Novartis Vaccines in Germany, Interim Head of Medical Affairs Europe at Seqirus, and medical launch lead for a dengue vaccine in non-endemic markets.

Dr. rer. physiol. in tumour immunology, University of Tübingen. MHBA, University of Erlangen-Nürnberg.

LinkedIn
Member

imunaris is a member of the Swiss Biotech Association, the industry association of the Swiss biotech sector.

swissbiotech.org

Tell us where you want to be in 12 months.

Write to us
Mail
info@imunaris.com
Office
imunaris GmbH
Ribibachstrasse 24, 3428 Wiler b. Utzenstorf, Switzerland

Talk to us

Tell us briefly what it is about. We reply within 2 working days.